At the news
? BULLISHIMPACT 6/10 PRESS-RELEASE filed Jun 9, 2026 at 08:30 ET
Disc Medicine announced alignment with the FDA that the ongoing Phase 3 APOLLO study, if successful, can serve as the basis for responding to the CRL for bitopertin in EPP and potentially support traditional approval. This provides a clearer path forward after the CRL, reducing regulatory uncertainty. APOLLO data is expected in Q4 2026, with an FDA decision by mid-2027.
- FDA aligned that successful Phase 3 APOLLO study can support CRL response and potentially traditional approval.
- APOLLO data expected in Q4 2026; CRL response submission by end of 2026.
- FDA decision on bitopertin expected by mid-2027.
- Bitopertin is a potential first disease-modifying therapy for EPP.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access